NASDAQ:ACB - Nasdaq - CA05156X8504 - Common Stock - Currency: USD
ACB gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. ACB has a bad profitability rating. Also its financial health evaluation is rather negative. ACB is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 1.44% | ||
ROE | 2.18% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | 3.9% | ||
GM | 3.82% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.07 | ||
Debt/FCF | N/A | ||
Altman-Z | -8.91 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.3 | ||
Quick Ratio | 1.6 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 29 | ||
Fwd PE | 18.91 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
4.64
0 (0%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 29 | ||
Fwd PE | 18.91 | ||
P/S | 1.1 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.61 | ||
P/tB | 0.72 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 1.44% | ||
ROE | 2.18% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | 3.9% | ||
GM | 3.82% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.07 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 86.17% | ||
Cap/Sales | 6.32% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.3 | ||
Quick Ratio | 1.6 | ||
Altman-Z | -8.91 |